Millie Long

26PUBLICATIONS
129CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pacific Peoples diet and nutritionAllergyInfant and child healthObstetrics and gynaecology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Oct 25, 2026
Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.

|Aug 14, 2026
Continued concomitant antibiotic or immunosuppression therapies reduce the risk of pouchitis among patients with ileal pouch-anal anastomosis and primary sclerosing cholangitis.

|May 20, 2026
High Rates of Seroprotection for Measles in Pediatric Patients With Inflammatory Bowel Disease.

|Mar 06, 2026
Long-Term Infant Outcomes After In Utero Biologic Exposure: Results From the Pregnancy Inflammatory Disease Neonatal Outcomes Registry.

Arushi Kohli, Millie D Long, Dawn B Beaulieu

|Feb 11, 2026
Previous Abdominal Surgery Is Not Associated With Adverse Pregnancy, Delivery, or Neonatal Outcomes in Women With Crohn's Disease: Results From the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes Study.

Erica Zurbuch, Uma Mahadevan, Samir Shah

|Jun 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the Pouch.

Edward L Barnes, Laura Raffals, Taha Qazi

Pageof 5

Frequent Collaborators

5 joint publications

Michael D Kappelman

3 joint publications

Raymond K Cross

3 joint publications

Wenli Chen

3 joint publications

Edward L Barnes